FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235- 0104					
Estimated average burden						
hours per	0.5					

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Srivastava Deepak</u>	Event Statement y/Year) 21	3. Issuer Name and Ticker or Trading Symbol Tenaya Therapeutics, Inc. [ TNYA ]						
(Last) (First) (Middle) C/O TENAYA THERAPEUTICS, INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
171 OYSTER POINT BLVD., 5TH FLR	_		Officer (give title below)	Other below)	(Specify   /	. Individual or Jo Check Applicable X Form filed Person		
(Street) SOUTH SAN FRANCISCO CA 94080	_						by More than One Person	
(City) (State) (Zip)								
Т	able I - Noi	n-Derivati	ive Securities Benefi	cially O	wned			
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owner Form: I (D) or In (I) (Insti	Direct ON	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock			191,666	D				
Common Stock			141,666	]	I Se	ee Footnotes <sup>(1)</sup>		
(e.ç			e Securities Beneficia nts, options, convert					
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration Day/ (Month/Day/)	ate	3. Title and Amount of Se Underlying Derivative Se (Instr. 4)		4. Conversion or Exercise Price of	cise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)	3,	
Stock Option (Right to Buy)			1	37,500	2.7	D	1	

## **Explanation of Responses:**

- 1. These shares are held directly by The J. David Gladstone Institutes for which the Reporting Person serves as President. The Reporting Person may be deemed to have voting and investment control over the shares. The Reporting Person disclaims beneficial ownership of these shares. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of any of the shares held by The J. David Gladstone Institutes for Section 16 or any other purpose.
- 2. 1/48th of the shares subject to the option granted on December 6, 2019 became vested and exercisable as of November 6, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date.

## Remarks:

Date set forth above represents the effective date of the Issuer's initial public offering

/s/ Leone Patterson
Attorney-in-Fact for

07/29/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Tenaya Therapeutics, Inc. (the Company), hereby constitutes and appoints Faraz Ali and Leone Patterson, and each of them, as the true and lawful attorney-in-fact of the undersigned to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and
- 2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of and transactions of the undersigned in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of July, 2021.

Signature:/s/Deepak Srivastava

Print Name: Deepak Srivastava